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Growing evidence indicates that sphingosine-1-P (S1P) upregulates glutamate secretion in hippocampal neurons. However, the molec-
ular mechanisms through which S1P enhances excitatory activity remain largely undefined. The aim of this study was to identify
presynaptic targets of S1P action controlling exocytosis. Confocal analysis of rat hippocampal neurons showed that S1P applied at
nanomolar concentration alters the distribution of Synapsin I (SynI), a presynaptic phosphoprotein that controls the availability of
synaptic vesicles for exocytosis. S1P induced SynI relocation to extrasynaptic regions ofmature neurons, as well as SynI dispersion from
synaptic vesicle clusters present at axonal growth cones of developing neurons. S1P-induced SynI relocation occurred in a Ca2-
independent but ERK-dependent manner, likely through the activation of S1P3 receptors, as it was prevented by the S1P3 receptor
selective antagonist CAY1044and inneurons inwhichS1P3 receptorwas silenced.Our recent evidence indicates thatmicrovesicles (MVs)
released by microglia enhance the metabolism of endogenous sphingolipids in neurons and stimulate excitatory transmission. We
therefore investigated whether MVs affect SynI distribution and whether endogenous S1P could be involved in the process. Analysis of
SynI immunoreactivity showed that exposure to microglial MVs induces SynI mobilization at presynaptic sites and growth cones,
whereas theuse of inhibitors of sphingolipid cascade identified S1Pas the sphingolipidmediating SynI redistribution.Ourdata represent
the first demonstration that S1P induces SynI mobilization from synapses, thereby indicating the phosphoprotein as a novel target
through which S1P controls exocytosis.
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Introduction
Sphingolipids are potent bioactive lipids, which have signaling
functions beyond their structural role in the nervous system
(Davletov and Montecucco, 2010; García-Martínez et al., 2013).
Their signaling action depends on mobilization from neuronal
membranes. The sphingolipid sphingosine (Sph) is produced
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Significance Statement
Growing evidence indicates that the bioactive lipid sphingosine and its metabolite sphingosine-1-P (S1P) stimulate excitatory
transmission. While it has been recently clarified that sphingosine influences directly the exocytotic machinery by activating the
synaptic vesicle proteinVAMP2 to formSNARE fusion complexes, themolecularmechanismbywhich S1P promotes neurotrans-
mission remained largely undefined. In this study,we identify Synapsin I, a presynaptic phosphoprotein involved in the control of
availability of synaptic vesicles for exocytosis, as the key target of S1P action. In addition, we provide evidence that S1P can be
produced at mature axon terminals as well as at immature growth cones in response to microglia-derived signals, which may be
important to stabilize nascent synapses and to restore or potentiate transmission.
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from plasma membrane sphingomyelin by sequential action of
sphingomyelinase and ceramidase and can be converted to its
polar metabolite sphingosine-1-P (S1P) by sphingosine kinase
(SphK).
Growing evidence indicates that sphingolipids stimulate trans-
mitter release from excitatory synaptic terminals. Externally added
Sph and S1P stimulate depolarization-induced glutamate release
from synaptosomes (Kajimoto et al., 2007; Darios et al., 2009) and
increase the rate of spontaneous glutamate transmission in hip-
pocampal slices or in cultures (Darios et al., 2009; Kanno et al.,
2010). Endogenous productionof Sphor S1P, triggered by sphingo-
myelinase activity, also activates exocytosis (Darios et al., 2009;
Okada et al., 2009; Kanno and Nishizaki, 2011; Antonucci et al.,
2012). Furthermore, knock-out of SphK-1, which is recruited to
presynaptic terminals in response to neuronal activity (Chan and
Sieburth, 2012), results in reduction of evoked transmitter and im-
pairment of long term-potentiation, spatial learning, and memory
(Kajimoto et al., 2007; Chan and Sieburth, 2012), confirming that
endogenous S1P crucially regulates synaptic activity.
Recently, it has been clarified that Sph, but not S1P, influences
directly the exocytotic machinery by activating the synaptic vesicle
(SV) protein VAMP2 to form SNARE fusion complexes (Darios et
al., 2009; Okada et al., 2009), a molecular event associated with SV
tethering (García-Martínez et al., 2013). Conversely, the molecular
mechanism by which S1P promotes neurotransmission remains
largely undefined.Unlike Sph, S1P, formed intracellularly at presyn-
aptic sites, may stimulate synaptic transmission by an extracellular
pathway, after release into the pericellular space and binding to its
cell surface receptors in paracrine or autocrine manners (Kajimoto
et al., 2007). S1P receptors Type 1 (S1P1), Type 2 (S1P2), Type 3
(S1P3), and Type 5 (S1P5) have been detected by immunofluores-
cence analysis inneurons (Doi et al., 2013;Kempf et al., 2014).How-
ever, the specificity of their labeling by available antibodies still
deserves to be assessed (Choi et al., 2011). Out of these receptor
types, S1P3 likely controls glutamate release frommossy fiber termi-
nals in the hippocampus (Kanno and Nishizaki, 2011; Choi and
Chun, 2013). However, the synaptic effectors of S1P receptors that
ultimately control exocytosis remain undefined. Here we identify
Synapsin I (SynI), a presynaptic phosphoprotein, as a key target of
extracellular S1P action, that promotes availability of SVs for
exocytosis.
Materials andMethods
Animals. All the experimental procedures followed the guidelines estab-
lished by the European Legislation (Directive 2010/63/EU) and the Ital-
ian Legislation (L.D. no 26/2014).
Cell cultures. Primary neuronal cultures were obtained from the hip-
pocampi of 18-d -old fetal Sprague Dawley rats of either sex (Charles
River), A-SMase KO or wild-type (WT) C57BL/6 mice (of either sex) as
described previously (Banker and Groslin, 1998; Antonucci et al., 2012).
Briefly, dissociated cells were plated onto poly-L-lysine (Sigma-Aldrich)
treated coverslips and maintained in Neurobasal with 2% B27 supple-
ment (Invitrogen), antibiotics, glutamine, and glutamate. Neurons were
used for experiments at 6 or 14 DIV. Primarymicroglia from P1 Sprague
Dawley rats were obtained and maintained as previously described (An-
tonucci et al., 2012).
Drugs and reagents. Stock solutions were prepared by dissolving the
following molecules: imipramine, PD98059, H89, ATP, SMase (all from
Sigma-Aldrich) in Krebs-Ringer solution (KRH, 25mMNaCl, 5mMKCl,
1.2mMMgSO4, 1.2mMKH2PO, 2mMCaCl2, 6mMD-glucose, and 25mM
HEPES/NaOH, pH 7.4); SK inhibitor (SKI) (Echelon Biosciences),
CAY1044 (Cayman Chemicals), and W146 (Avanti Polar Lipids) in
DMSO; OEA (Sigma-Aldrich) in ethanol, S1P (Enzo Biochem), and
S-FTY720-vinylphosphonate (kind gift from Prof. Robert Bittman) in
fatty acid free BSA (4mg/ml in PBS). Stock solutions were then diluted in
fresh medium and administered to neurons.
Microvesicle (MV) isolation and characterization. MVs shed from mi-
croglia upon exposure to 1 mM ATP for 30 min in KRH were pelleted at
10,000 g after preclearing from cells and debris as described previously
(Gabrielli et al., 2015). Routinely, protein content of MVs was deter-
mined by Micro BCA protein assay kit (Thermo Fischer Scientific),
whereas the number and dimension of MVs were assessed using Nano-
sight LM10-HS system (Malvern Instruments) configured with a 405 nm
laser and EMCDD camera (Hamamatsu Photonics). Videos were col-
lected and analyzed using the NTA software (version 2.3), with the min-
imal expected particle size, minimum track length, and blur setting all set
to automatic. Camera shutter speed was fixed at 15 ms, and camera gain
was set to 300. Room temperature was ranging from 25°C to 28°C. MV
pellets were resuspended in 400 l of 0.1 m-filtered sterile KRH, and
five recordings of 30 s were performed for each sample. No particles were
detected in 0.1mfiltered sterile KRH.MVswere used immediately after
isolation. The 1.7  105 neurons were incubated with 1.42 g of MVs
produced by primarymicroglia in amicroglia-to-neuron ratio of 2:1, for
30 min at 37°C, corresponding to a concentration of 3.55 g/ml, ob-
tained diluting MVs in 400 l of medium.
Immunofluorescence staining.Neuronal cultureswere fixed in PBSwith
4% PFA and 4% sucrose. The following antibodies were used: mouse
anti-SynI (1:100), guinea pig anti-Bassoon (1:300), rabbit anti-SV2 (1:
300), rabbit anti-vesicular glutamate transporter 1 (VGLUT1) (1:1000)
(all from Synaptic Systems), human anti-glutamic acid decarboxylase
(1:100) (from serum of patients, kindly provided by Prof. M. Solimena,
Dresden, Germany), rabbit anti-tubulin (1:80, Sigma-Aldrich), rabbit
anti-S1P3 (1:100, Cayman Chemicals), and mouse anti-PSD95 (1:400,
NeuroMab). Secondary antibodies were conjugated with Alexa-488,
Alexa-568, Alexa-633 (Invitrogen). Images were acquired using a Leica
SPE confocal microscope equipped with an ACS APO  63/1.30 oil
objective (Leica Microsystems). Fluorescence image processing was per-
formed with ImageJ Software (National Institutes of Health).
Analysis of SynI dispersion. Acquisition parameters (i.e., laser power,
gain, and offset) were kept constant among different experimental set-
tings. To quantify the degree of SynI dispersion (dispersion index) in
growth cones, the profile of SynI fluorescence was measured along arbi-
trary lines in growth cones by using ImageJ software. The number of
peaks per micron (peak density), which reflects the number of SynI clus-
ters, was counted in the plot profile by putting threshold equal to 100
arbitrary units. Ratio between the mean peak density from treated and
control cultures was subtracted from the value of 1 to obtain the disper-
sion index. For the quantification of SynI dispersion as cone fraction,
excitatory coneswith dispersion index0.2were considered as dispersed
(Gelsomino et al., 2013). Unless otherwise mentioned, only quite large
growth cones (8 10 m in length/width) were analyzed. Such large
growth cones belong to excitatory neurons, whereas inhibitory cones are
5 4 m in size at 6 DIV. At synapses, SynI dispersion was quantified
as follows: SynI and Bassoon double-positive puncta (i.e., synaptic SynI
puncta) were revealed by generating a SynI/Bassoon double-positive im-
age using the ‘and’ option of ‘image calculator’ function. Total colocal-
izing area was quantified using the ‘analyze particle’ function. Total SynI
fluorescence area was measured in SynI fluorescence images. Finally,
synaptic SynI (SynI-Bassoon colocalizing area) area was normalized to
total SynI area in each field, and the ratio was considered as an index of
Syn redistribution out of synaptic sites. All data are results of at least three
independent experiments.
RNA interference. The 2 DIV hippocampal neurons were incubated
with S1P3-specific Accell smart pool siRNAs or nontargeting control
pool siRNAs (1:500, Dharmacon, Carlo Erba Reagents) for 96 h (two
additions, every 48 h). Neurons were then fixed or lysated and S1P3
protein levels evaluated by immunofluorescence or Western blotting
analysis, respectively.
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Ca2 imaging. The 6 DIV hippocampal neurons were loaded with 2
M Fura-2 pentacetoxy methylester for 40 min at 37°C, washed and
transferred to the recording chamber of an inverted microscope (Axio-
vert 100; Zeiss) equipped with a Ca2 imaging unit Polychrome V (TILL
Photonics) as described previously (Verderio et al., 2004). Images were
collected with a CCD Imago-QE camera (TILL Photonics) and analyzed
with TILLvisION 4.5.66 software. After excitation at 340 and 380 nm
wavelengths, the emitted light was acquired at 505 nm at 1 Hz. [Ca2]i
was expressed as F340/F380 fluorescence ratio. The ratio values in se-
lected region of interest corresponding to neuronal cell bodies or growth
cones were calculated from sequences of images to obtain temporal
analysis.
Western blotting. Neurons were lysed in Laemmli buffer, separated by
electrophoresis, blotted on nitrocellulose membrane filters, and probed
using rabbit anti-ERK 1/2, anti-P-ERK 1/2 T202/Y204 (1:1000; Cell Sig-
naling Technology ), mouse anti-synapsin I (1:1000), mouse anti-SV2
(1:1000), rabbit anti-VGLUT1 (1:1000) (all from Synaptic Systems), rab-
bit anti-phosphosite 4,5-synapsin (1:3000 (Jovanovic et al., 1996),mouse
anti-Bassoon (1:500; Stressgen), rabbit anti-S1P3 receptor (1:1000; Cay-
man Chemicals), mouse anti-3 tubulin (1:4000; Promega). Photo-
graphic development was by chemiluminescence (GE Healthcare)
according to the manufacturer’s instructions. Western blot bands were
quantified by ImageJ software.
Electrophysiology. Whole-cell voltage-clamp recordings were performed
using a MultiClamp 700A amplifier (Molecular Devices) coupled to a
pCLAMP 10 Software (Molecular Devices), and using an inverted Axiovert
200microscope (Zeiss). Experiments were performed at room temperature
(20°C–25°C) in the external control solution KRH. Signals were sampled at
10 kHz and filtered to 4 kHz.Miniature EPSCs (mEPSCs) were recorded at
70mV in the presence of 1MTTX (Tocris Bioscience), using the follow-
ing internal solution: 130mMpotassiumgluconate,10mMKCl, 1mMEGTA,
10mMHEPES, 2mMMgCl2, 4mMMgATP, 0.3mMTris-GTP, and analyzed
using Clampfit software. For measurements of the readily releasable pool
(RRP), hypertonic solution containing 6 mM sucrose was infused with a
puffer pipette for 4 s in the extracellular solution KRH. Before stimulation,
mEPSCs were recorded for 1 min to evaluate the miniature quantal charge.
The ratio between the charge transferred by sucrose delivery with respect to
the quantal charge of miniature events indicated the number of readily re-
leasable vesicles (Rosenmund and Stevens, 1996).
Statistical analysis. All data are presented as mean  SEM from the
indicated number of experiments (N). Statistical analysis was performed
using Graphpad Prism 6.0 software (Graphpad Software). After testing
data for normal distribution, the appropriate statistical test has been used
(see figure legends).
Results
S1P induces dispersion of SynI immunoreactivity in the
growth cones of excitatory hippocampal neurons
Axonal growth cones of excitatory neurons represent an ideal
compartment to analyze the spatial distribution of molecules
controlling SV fusion upon S1P stimulation as they are quite
large structures, up to 40–50 m in size, enriched in SVs (Bo-
nanomi et al., 2005; Schenk et al., 2005; Gelsomino et al., 2013).
Among components of the exocytotic machinery, SynI is a major
regulatory phosphoprotein, which controls the availability of SVs
for exocytosis, by tethering them to each other and to the actin
cytoskeleton (Cesca et al., 2010; Fornasiero et al., 2010). There-
fore, SynI is a good candidate for mediating changes in neu-
rotransmitter release. Confocal analysis showed that S1P
administration at 50 nM for 30 min induced relocation of SynI
from a clustered to a fully dispersed distribution, in axonal
growth cones of developing hippocampal neurons (Fig. 1A,A).
The effects of S1P were reversible, and growth cones fully recov-
ered a clustered SynI distribution 5 h after S1P removal (Fig.
1A,A). SynI relocation was quantified by calculating the immu-
noreactivity dispersion index (Fig. 1B) and the fraction of cones
with dispersed SynI distribution (Fig. 1C) in control and S1P-
treated neurons (see Materials and Methods). Growth cones re-
sponding to S1Pwere found to be 70.642 4.369%and belonged
mostly to excitatory neurons, unequivocally identified by stain-
ing for theVGLUT1 (Fig. 1D). Indeed, no significant alteration of
SynI distributionwas induced by S1P in growth cones of GABAe-
rgic neurons, identified by glutamic acid decarboxylase staining
(Fig. 1D; dispersion index: ctrl 0 0.083, S1P 0.1768 0.044). At
6 DIV, inhibitory cones were rather small (maximum length:
5.3 0.35 m; maximum width; 3.97 0.39 m; N	 40), and
most of them lacked a flattened lamellipodium. Given their small
size, GABAergic growth cones were likely excluded by all subse-
quent analyses, which were performed in quite large cones, larger
than 8 10 m in size. Relocation of SynI was paralleled by SV
dispersion, as evidenced by staining for VGLUT1 (Fig. 1E,E),
suggesting dissociation of SVs from the actin cytoskeleton.West-
ern blotting analysis revealed that SynI and VGLUT1 protein
levels remained constant after S1P treatment, thus excluding that
the reduction in the SynI/VGLUT1 clustered fluorescence may
result from protein degradation (Fig. 1F).
Dispersion of SynI immunoreactivity by S1P occurs through
S1P3 and ERK/MAPK pathway
To explore the involvement of S1P receptors in S1P-induced SynI
dispersion, neurons were preincubatedwith the full antagonist of
S1P1–3-5 S-FTY720-vinylphosphonate (100 nM) (Valentine et al.,
2010), the selective S1P3 antagonist CAY1044 (10 M) (Koide et
al., 2002; Pyne and Pyne, 2011), or the selective S1P1 antagonist
W146 (10 M) (Di Menna et al., 2013). Both the general block of
S1P receptors and the selective block of S1P3 largely prevented
S1P-induced SynI dispersion at growth cones (Fig. 2A), indicat-
ing a role for S1P3 in the control of SynI location. Selective block
of S1P1 produced a much less pronounced, but still significant,
inhibition of SynI relocation (Fig. 2A). Antagonists alone did
not have any effect on SynI distribution (data not shown). To
confirm the involvement of S1P3 in SynI dispersion, we
knocked down the receptor by exposing developing neurons
to S1P3-specific pool siRNAs for 96 h. S1P3 downregulation
was assessed by immunofluorescence staining and Western
blotting (Fig. 2B,C). We found that S1P-mediated SynI redis-
tribution was largely prevented in neurons in which S1P3 was
silenced but not in neurons exposed to nontargeting control
pool siRNAs (Fig. 2D).
S1P3 is coupled to several heterotrimeric G-proteins and
effector kinases (Choi and Chun, 2013), including PKA,
CaMKs, and ERK/MAPK, which phosphorylate SynI at multi-
ple sites and decrease the binding of the protein to SVs and/or
F-actin (Cesca et al., 2010). We first explored the involvement
of Ca 2 mobilization and Ca2-dependent kinases in SynI
dispersion triggered by S1P receptors. As previously described
(Giussani et al., 2007), single-cell Ca 2 imaging experiments
showed the lack of Ca2 responses to 10–100 nM S1P in
growth cones or cell bodies of developing neurons, loaded
with the Ca2 dye FURA-2 (Fig. 2E; no growth cones showed
Ca2 response, N 	 20; no cell body showed Ca2 response,
N 	 34). Consistently, SynI dispersion still occurred in neu-
rons loaded with the Ca2 chelator BAPTA and challenged
with S1P in Ca2-free medium (Fig. 2F ). Collectively, these
findings excluded a role of Ca2 mobilization and Ca2-
dependent kinases in SynI dispersion. We next investigated
the possible involvement of ERK/MAPK and PKA pathways
in the process. Western blotting of developing neurons with
antibodies recognizing the phosphorylated form of ERK 1/2
(p-ERK) showed a significant increase of ERK 1/2 phosphor-
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ylation level in response to 50 nM S1P (ctrl 1.013  0.01033;
S1P 1.857  0.1099; N 	 3, t test p 	 0.0044). Accordingly,
S1P-induced SynI dispersion was largely prevented by the spe-
cific MEK1 inhibitor PD98059 (30 M), but not by the PKA
inhibitor H89 (10 M), thus selectively involving ERK 1/2
signaling pathways in SynI relocation (Fig. 2G). To provide a
direct demonstration that ERK-dependent phosphorylation
of SynI was involved in S1P action, neurons were exposed or
not to S1P and analyzed by Western blotting with specific
antibodies for SynI phosphorylated by ERK at sites 4 and 5. A
significant increase in SynI phosphorylation was detected 5–8
min after S1P treatment (Fig. 2H ).
Endogenous S1P controls SynI distribution in axonal
growth cones
We have recently shown that microglia, the immune cells of the
nervous system, release extracellularMVs, which enhance sphin-
golipid metabolism in neurons and stimulate excitatory trans-
mission (Antonucci et al., 2012; Gabrielli et al., 2015). Thus, we
used microglia-derived MVs to stimulate sphingolipid metabo-
lism, trigger production of Sph and S1P in neurons, and test
whether endogenous S1P may regulate SynI distribution. Con-
centration and dimension of MVs produced by cultured micro-
glia were assessed by Nanosight Tracking Analysis (Fig. 3A),
whereas protein content of MVs was evaluated by BCA protein
Figure1. Lownanomolar S1P induces dispersion of SynI immunoreactivity in growth cones.A, Immunofluorescence of 6 DIV hippocampal neurons treated or notwith S1P (50 nM) for 30min and
fixed immediately or 5 h after S1P treatment. Neurons are stained for SynI in green and tubulin in red. SynI is clustered in small puncta in control neurons (top), becomes dispersed after S1P exposure
(middle), and reacquires a clustered distribution 5 h after S1P removal (bottom). Scale bar, 10m. A, Fluorescence intensity plot (gray levels) of SynI along lines depicted in A.B, Quantification of
SynI dispersion under the different experimental conditions (dispersion index, ctrl	 0.047 0.03026; S1P	 0.7179 0.07696; S1Pwash	0.09127 0.0183, one-way ANOVA p 0.001,
Holm–Sidak’smultiple-comparison test). C, Fraction of cones with dispersed SynI under the different experimental conditions (ctrl	 1 0.054; S1P 2.784 0.255; S1Pwash	 1.086 0.072,
N	 3, Kruskal–Wallis one-way ANOVA p 0.001, Dunn’s multiple-comparison test). D, Fraction of cones with dispersed SynI in control and S1P-treated excitatory or inhibitory hippocampal
neurons (VGLUT1neurons: ctrl	10.222; S1P	4.8661.655;N	3,Mann–WhitneyRankSumTestp	0.008; glutamic aciddecarboxylaseneurons: ctrl	10.108; S1P	1.586
0.242;N	3,Mann–WhitneyRankSumTestp	0.343).E,E, Immunofluorescence (E) andplot profiles of fluorescence intensity (E) showing relocationof SynI andV-GLUT1at growth cones after
exposure to S1P. Peak fluorescence of SynI and VGLUT1 decreases and the intensity profiles of SynI and VGLUT1 fluorescence becomemore uniformly distributed in S1P-treated neurons. F, Western
blottinganalysis of developingneurons showing lackofdegradationof SynI andVGLUT1after S1P treatment.3 tubulin is usedas sample loading control. *p0.05. **p0.01. ns,Not significant.
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assay. Incubation of neurons with microglial MVs (3.55 g
protein/ml) for 30 min produced a clear dispersion of SynI in
axonal growth cones (Fig. 3B,B), as indicated by the analysis
of dispersion index or by the fraction of dispersed growth
cones (dispersion index: ctrl 0  0.1; MVs 0.4561  0.1104;
N	 5, t test p	 0.0129; cone fraction: ctrl 0.145 0.024; MVs
0.4082  0.045; N 	 14, t test p  0.0001). SynI dispersion
evoked by MVs was largely prevented by preincubation of
neurons with specific inhibitors of the sphingolipid cascade:
the acid sphingomyelinase inhibitor imipramine (1 M),
which blocks sphingomyelin metabolism to ceramide; the ce-
ramidase inhibitor N-oleoylethanolamine (37 M OEA),
which inhibits ceramide metabolism to sphingosine (Strelow
et al., 2000); or the sphingosine kinase inhibitor SKI-1 (2 M),
which prevents biosynthesis of S1P from Sph (Kanno et al.,
2010) (Fig. 3C). Accordingly, SynI dispersion evoked by MVs
Figure 2. S1P-induced dispersion of SynI is mediated mainly by S1P3 via MAPK. A, Fraction of growth cones characterized by dispersed SynI in control neurons or neurons exposed to S1P upon
different pharmacological treatments. Application of either the pan S1P receptors inhibitor S-FTY720-vinylphosphonate (S-FTY) or the S1P3 selective antagonist CAY10444 (CAY) fully prevents SynI
relocation. The S1P1 selective antagonist W146 inhibits SynI dispersion to a lower extent (ctrl 0.985 0.1077; S1P 2.534 0.1069; S1PS-FTY 1.414 0.3171; S1PCAY 1.015 0.017; S1P
W146 1.822 0.1228;N	 4, one-way ANOVA p 0.001, Holm–Sidak’smultiple-comparison test).B, Immunolabeling for S1P3 (red) and SynI (green) in 6 DIV hippocampal neurons. Note the
decrease in S1P3 immunoreactivity in neurons treatedwith S1P3-specific siRNAs. C, Western blotting analysis of neurons treatedwith S1P3-specific siRNAs orwith nontargeting siRNAs for S1P3.3
tubulin is used as loading control (Student’s t test p	 0.0051). D, Fraction of growth cones characterized by dispersed SynI under S1P treatment in control neurons, neurons treated with
S1P3-specific siRNAs, or nontargeting control siRNAs (nontargeting siRNA-treated neurons: ctrl 1 0.059, S1P 2.073 0.070; t test p 0.001; S1P3-siRNA-treated neurons: ctrl 1.015 0.068,
S1P 0.699 0.083; t test p	 0.074). E, Representative temporal plot of [Ca 2]i responses (measured as variation in the F340/F380 fluorescence ratio) induced by application of 100 nM S1P,
followed by depolarizationwith 30mMKCl in the cell body and the axonal growth cone of a developing neuron. F, Analysis of S1P-induced SynI dispersion, expressed as normalized fraction of cones
withdispersedSynI staining, in either control neurons (Ca 2) or neuronsmaintained inCa 2-freemediumand loadedwith the cell-permeable Ca 2 chelatorBAPTA (Ca 2). Intracellular and
extracellular Ca 2 chelation does not impact on SynI dispersion induced by 50 nM S1P (ctrlCa 0.988 0.125; S1PCa 2.136 0.31; ctrl-Ca 2 1.228 0.037; S1P-Ca 2 2.379
0.152;N	 3, one-way ANOVA p	 0.0008, Holm–Sidak’s formultiple-comparison test).G, Fraction of growth cones characterized by dispersed SynI in control neurons and in neurons treatedwith
S1P in the presence of either theMEK inhibitor PD98059 or the PKA inhibitor H89. Application of PD98059 prevents SynI relocation (ctrl 1.008 0.039; S1P 2.487 0.364; S1PPD98059 1.107
0.150; S1PH89 2.099 0.159;N	 3, one-way ANOVA p	 0.0027, Holm–Sidak’s formultiple-comparison test).H, Western blotting of 6 DIV neurons for phosphosites 4/5 Syn (P-4/5 Syn) and
total SynI. Quantification shows phosphorylation of SynI at ERK sites after treatmentwith 50 nM S1P (one-way ANOVA p	 0.0439, Kruskal–Wallis formultiple-comparison test). *p 0.05. **p
0.01. ***p 0.001. ns, Not significant.
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did not occur in acid sphingomyelin knock-out (ASMase/)
neurons, in which S1P biosynthesis from sphingomyelin is
genetically impaired (Fig. 3D), whereas it could be induced by
application of exogenous sphingomyelinase (cone fraction:
ctrl 0.16  0.06; A-SMase-treated 0.773  0.028; N 	 3, t test
p 	 0.0008). Similarly to exogenous S1P, endogenous S1P,
produced upon neuron exposure to microglial MVs, triggered
SynI dispersion by an extracellular action, acting on S1P3.
Indeed, SynI redistribution was blocked by the pan S1P antag-
onist S-FTY720-vinylphosphonate and the S1P3 selective an-
tagonist CAY1044, but not by the S1P1 selective antagonist
W146 (Fig. 3E). SynI relocation, induced by extracellular S1P
generated upon treatment with MVs, occurred in a Ca2-
independent (Fig. 3F ) but ERK-dependent manner, as it was
Figure 3. Endogenous S1P induces SynI dispersion in growth cones. A, Representative size profile of MVs isolated by differential centrifugation at 10,000 g from the supernatant of 1 10 6
primarymicroglial cells after removal of cellular debris, resuspended in 400l of 0.1m-filtered sterile KRH and analyzed by Nanosight. B, B, Fluorescence images of growth cones, from control
(top) or MVs-treated (bottom) neurons, stained for SynI. The relative plot profiles of fluorescence intensity along arbitrary lines (white lines) are shown in B. Scale bars, 10m. C, Quantification
of SynI dispersion (cone fraction) in neurons treated with MVs in the presence or absence of the A-SMase inhibitor imipramine (imi), the ceramidase inhibitor OEA, and the sphingosine kinase
inhibitor SKI-1 (ctrl 1.0220.186;MVs 2.9860.214;MVsimi 1.1830.336;MVsOEA1.5630–412;MVsSKI-1 1.5380.066;N	3–5, one-wayANOVAp	0.0028, Holm–Sidak’s
formultiple-comparison test).D, Dispersion of SynI in developing neurons established fromWTorA-SMaseKOmice. Data are expressed as dispersed cone fraction (WT ctrl 1 0.15;WTMVs 2.04
0.095; KO ctrl 1 0.118; KOMVs 0.997 0.072;N	 3, t test p	 0.021). E, Graphs represent the fraction of growth cones displaying dispersed SynI upon various pharmacological treatments. The
pan S1P receptor antagonist (s-FTY) and the selective S1P3 antagonist (CAY), but not S1P1 antagonist (W146), fully prevent SynI relocation in response to MVs (ctrl 0.961 0.055; MVs 2.231
0.063; MVsS-FTY 1.157 0.111; MVsCAY 1.099 0.177; MVsW146 1.819 0.48; N	 3–7, one-way ANOVA p 0.0001, Holm–Sidak’s multiple-comparison test). F, Chelation of
extracellular and intracellular Ca 2does not influence SynI relocation evokedbyMVs (ctrlCa 210.254;MVsCa 22.4610.242; ctrl-Ca 21.1060.1;MVs-Ca 22.0630.091;N	
3; one-wayANOVAp	0.013, Holm–Sidak’s formultiple-comparison test).G, Application of theMAPK inhibitor PD98059prevents SynI relocation evokedbyMVs (ctrl 0.9990.355;MVs 3.671
0.555; MVsPD98059 1.258 0.296; N	 3, one-way ANOVA p	 0.028, Holm–Sidak’s for multiple-comparison test). *p 0.05. **p 0.01. ***p 0.001.
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almost completely prevented by the spe-
cific ERK inhibitor PD98059 (30 M)
(Fig. 3G).
S1P-induced SynI relocation occurs
upstream glutamate release
Our previous evidence indicates that acti-
vation of presynaptic AMPA receptors in-
duces ERK 1/2 phosphorylation and SynI
dispersion at growth cones (Schenk et al.,
2005). Thus, endogenous glutamate, re-
leased upon S1P stimulation, may induce
SynI dispersion through activation of pre-
synaptic AMPA receptors. This would im-
ply that SynI is a target rather than a
promoter of glutamate release. To address
this possibility, neurons were stimulated
with S1P or microglial MVs in the pres-
ence of the AMPA receptor antagonist
CNQX (10 M). In both cases, SynI dis-
persion was unaffected by CNQX, indi-
cating that SynI does not redistribute as a consequence of
enhanced glutamate release and presynaptic glutamate receptor
stimulation (Fig. 4A,B).
S1P affects SynI distribution at the mature synapse
Wenext investigatedwhether S1P also affects SynI distribution in
the presynaptic compartment of fully developed neurons; 14–16
DIV neurons were exposed to 50 nM S1P for 30 min, fixed, and
counterstained for the presynaptic active zone protein Bassoon.
We observed a reduction of the typical punctuate staining of SynI
upon challenge with S1P, whereas staining for Bassoon remained
punctuate (Fig. 5A,A). Accordingly, a clear decrease in the ratio
between synaptic and total SynI immunoreactivity wasmeasured
in neurons exposed to S1P (Fig. 5B). Colocalization analysis for
the SV integral protein SV2 (Bassoon/SynI/SV2) revealed that
SynI dispersion was accompanied by SV relocation into the peri-
synaptic area (Fig. 5A,A). Conversely, postsynaptic density or-
ganization was unchanged. Indeed, PSD-95 staining remained
strictly punctate after S1P application (Fig. 5C), and no changes
of the mean size of PSD95 clusters were observed (mean size
m2: ctrl 0.1562  0.019; S1P 0.1519  0.004; N 	 3). The
presynaptic action of S1P was reversible, prevented by the S1P3
receptor antagonist CAY1044 (Fig. 5B) and not associated with
synaptic protein degradation (Fig. 5D), similarly to the S1P ac-
tion at the developing growth cone.
A similar redistribution of SynI immunoreactivity was ob-
served in response to microglial MVs (Fig. 5E), which enhance
Sph/S1P metabolism from neuronal plasma membrane. SynI re-
location to extrasynaptic regions evoked by S1P was largely pre-
vented by inhibitors of the sphingolipid cascade (Fig. 5E).
S1P increases the size of ready releasable pool of SVs
The next step was to investigate how the activation of S1P recep-
tors and SynI dispersion impact neurotransmission. Analysis of
mEPSCs revealed lack of changes in either mEPSC frequency
(ctrl 	 2.1563  0.24406 Hz vs 2.53015  0.30 Hz; Fig. 6B) or
amplitude (ctrl	 20.3563 1.54 pA vs 22.77733 1.88 pA; Fig.
6C) in neurons treated with nanomolar S1P (50 nM) for 40 min
(Fig. 6A–C). However, analysis of quantal charge revealed re-
duced charge transfer in S1P-treated neurons with respect to the
untreated cells (Fig. 6D), suggesting an effect of S1P on postsyn-
aptic AMPA receptors. Exposure of neurons to S1P in the pres-
ence of S1P3 inhibitor CAY1044 did not alter frequency and
amplitude of excitatory miniature events (Fig. 6A–C; S1PCAY:
frequency 	 2.632  0.249 Hz; amplitude 	 20.266  1.70318
pA) but produced a partial recovery of the quantal charge reduc-
tion associated to S1P treatment (Fig. 6D; ctrl	 129.154 13.82
pC; S1P 	 85.055  14.64 pC; S1PCAY 	 107.301  14.74
pC). We next estimated the size of the readily releasable pool of
synaptic vesicles (RRP) in response to local applications of hyper-
tonic sucrose solution (4-s-long; Fig. 6E,F). The total charge
transferred during the sucrose-evoked EPSCs was not different
between control, S1P-treated cultures, and S1PCAY neurons
(Fig. 6E,F; ctrl	 1127.54 134.36 pC; S1P	 1039.46 166.52
pC; S1PCAY 	 782.55  103.017 pC), but a significant in-
crease in the number of released vesicles was observed in S1P-
treated neurons (Fig. 6G), which was fully normalized by
application of the S1P3 antagonist CAY1044 (Fig. 6G; ctrl 	
1.00  0.095 vs 1.87  0.197 normalized value; S1PCAY 	
1.29  0.14; t test ctrl vs S1P: p 	 0.038). Thus, all these data,
together with immunocytochemical results, indicate that Syn-I
dispersion evoked by S1P3 activation associates with an increased
number of releasable SVs.
Discussion
Here we identify SynI, a phosphoprotein that controls the avail-
ability of SVs for exocytosis, as the molecular target mediating
extracellular action of S1P on excitatory synapses. By quantitative
immunofluorescence analysis, we show that S1P, applied at
nanomolar concentrations (50 nM), activates ERK/MAPK via
S1P3 receptors and influences the spatial organization of SynI,
both in the growth cones and at mature axon terminals of hip-
pocampal neurons. S1P action is relatively fast, as SynI relocation
occurs within 30 min from S1P application. ERK/MAPK path-
way, through phosphorylation of SynI at sites 4, 5, and 6 (Cesca et
al., 2010), is known to decrease SynI interaction with actin but
not with SVs (Jovanovic et al., 2001; Cesca et al., 2010). Accord-
ingly, we show that, upon S1P application, SynI is phosphory-
lated and redistributes along with SV markers to the presynaptic
regions of mature synapses and in the growth cones. In fully
developedneurons,mobilization of SVs increases the size of RRP,
estimated bymeasuring responses to high sucrose solution, with-
out changing the rate of spontaneous quantal events. The selec-
tive action of S1P-induced SynI dispersion in evoked but not
Figure 4. S1P induces SynI relocation upstreamglutamate release.A,B, Graphs represent normalized fraction of growth cones
displaying dispersed SynI in control neurons, neurons exposed to S1P (A) or exposed tomicroglia-derivedMVs (B) in the presence
or absence of the AMPA receptor antagonist CNQX (A: ctrl 1.00 0.22; S1P 2.613 0.076; S1PCNQX/APV 2.701 0.063;N	
3, one-way ANOVA p  0.0001, Holm–Sidak’s for multiple-comparison test. B, ctrl 1.001  0.03; MVs 2.128  0.088;
MVsCNQX/APV 1.982 0.084, N	 3, one-way ANOVA p 0.0001, Holm–Sidak’s for multiple-comparison test). ***p
0.001.
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spontaneous transmission is in agreement with a previous study,
which associated SynI dispersion, evoked by PKA, to larger RRP
of SVs and to enhanced transmission under sustained stimula-
tion but not basal condition (Menegon et al., 2006). Interestingly,
the larger pool of releasable SVs following SynI dispersion coun-
teracted synaptic depression and accelerated recovery from de-
pression (Menegon et al., 2006), suggesting that extracellular S1P
may increase synapse resistance to fatigue. Our results are also
consistent with the evidence that impaired S1P production does
not influence quantal release from motor terminals in C. elegans
mutants, lacking Sph kinase (Chan et al., 2012). Other studies
reported that application of high nanomolar ormicromolar con-
centrations of S1P significantly increases mEPSC frequency in
hippocampal slices or cultures (Kajimoto et al., 2007; Kanno et
al., 2010; Kanno and Nishizaki, 2011; Antonucci et al., 2012).
However, high concentrations of S1P may impact spontane-
ous glutamate transmission through intracellular targets
rather than extracellular action, consistent with the recent
identification of several proteins that bind S1P within cells
(Kunkel et al., 2013).
Figure 5. S1P-mediated SynI relocation at mature synapses. A, Confocal images showing synaptic contacts triple stained for SynI (green), the SV protein SV2 (red), and the active zone protein
Bassoon (blue) in 14DIV neuronsmaintained in control conditions or exposed tomicroglia-derivedMVs or S1P. Scale bars, 10m.A, Fluorescence intensity profiles of SynI, SV2, and Bassoon along
thewhite lines depicted inA (top images) showSynI and SV relocation after S1P orMVs exposure.B, Quantification of synaptic versus total SynI area inmature neurons fixed either immediately after
S1P treatment or 5 h after S1P removal (S1P wash), and in neurons pretreated with the S1P3 receptor antagonist CAY10444 (synaptic/total SynI area, ctrl 1.000; S1P 0.640 0.041; S1P-wash
1.170 0.106; CAYS1P 0.944 0.145,N	 3, normalized data, one-way ANOVA p 0.001, Holm–Sidak’smultiple-comparison test; for details, seeMaterials andMethods). C, Representative
imagesof 14DIV cultures stained for thepostsynaptic proteinPSD-95 (green) and tubulin (red). Scale bars, 5m.D,Westernblottinganalysis ofmatureneurons showing lack of degradationof SynI,
Bassoon (Basn), VGLUT1, and SV2 under S1P treatment for 30 min.3 tubulin is used as sample loading control (Student’s t test: SynI p	 0.8497, Bassoon p	 0. 8968,VGLUT1 p	 0.9967, SV2
p	 0.6362). E, Quantification of SynI dispersion evoked by microglia-derived MVs in the presence or not of inhibitors of sphingolipid metabolism (synaptic/total SynI area, normalized to control:
ctrl 0.99 0.0002; MVs 0.48 0.06; MVsOEA 0.9375 0.1424; MVsSKI-I 0.8198 0.062; MVsS-FTY 0.9177 0.1205; N	 3, one-way ANOVA p	 0.0063, Holm–Sidak’s for
multiple-comparison test). *p 0.05. **p 0.01.
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The extracellular action of S1P on excitatory transmission dif-
fers from that of its lipid precursor Sph which, by activating
VAMP-2 to form SNARE fusion complexes, upregulates not only
evoked but also spontaneous glutamate transmission in hip-
pocampal neurons and neuromuscular junctions (Darios et al.,
2009; Antonucci et al., 2012). It is worth noting, however, that
both Sph and S1P increase the size of SVs ready to be exocytosed
during stimulation (RRP) (Darios et al., 2009; Antonucci et al.,
2012; current study). Thus, RRP appears an important target
downstream Sph and S1P production, supporting the idea that
the two sphingolipids promote glutamate release through either
distinct or codependent mechanisms (Chan et al., 2012).
Identification of the mechanism of action by which S1P pro-
motes exocytosis is of high relevance, not least because of the
extensive use of the S1P1,3,4,5 agonist Fingolimod in the treatment
of multiple sclerosis (Cohen et al., 2010; Kappos et al., 2010). As
the S1P parent compound diffuses into the brain, where it even
accumulates (Foster et al., 2007; Hait et al., 2014), it is becoming
increasingly important to better define its action on brain cells,
including neurons.
On the other hand, which are the stimuli that trigger neurons
to endogenously produce and secrete S1P, promoting evoked
exocytosis via SynI dispersion? In rat hippocampal neurons, de-
polarization regulates Sph kinase-1 translocation from cytosol to
presynaptic membranes, which results in S1P accumulation at
the synapse (Kajimoto et al., 2007). Similarly, inC. elegans, S1P is
produced in response to neuronal activity, thanks to the recruit-
ment of Sph kinase to presynaptic regions of motor neurons
following muscarinic signaling (Chan and Sieburth, 2012; Chan
et al., 2012). However, we recently showed that sphingolipid me-
tabolism can be also regulated at the synapse by non-neuronal
cells.We identifiedmicroglia, the brain resident immune cells, as
a source of lipid messengers, which enhance ceramide and Sph
production in rodent neurons, through activation of acid sphin-
gomyelinase (Antonucci et al., 2012). Neuroactive lipids are se-
creted by reactivemicroglia through extracellularMVs and signal
to neurons upon MV contact with the neuronal surface (Anto-
nucci et al., 2012). We here provide evidence that the sphingo-
lipid cascade induced bymicroglial MVs does not stop at Sph but
proceeds to S1P, which participates to presynaptic stimulation
downstream Sph by selectively targeting SynI.
Stimulation of S1P production at axon terminals induced by
MVsmay be an important mechanism for microglia to restore or
potentiate glutamate transmission. At mature synapses, micro-
Figure 6. Low nanomolar S1P increases the size of RRP without influencing mEPSC frequency. A–D, Quantification of mEPSC frequency, amplitude, and quantal charge of 14 DIV hippocampal
neurons in control conditions or incubated for 40 min with S1P in the presence or absence of CAY10444. E, Representative sucrose-induced responses under the same conditions as in A. F, G,
Quantitative analysis of charge transfer and number of released vesicles measured in hippocampal neurons after hypertonic solution stimulation. The number of vesicles corresponds to the ratio
between the total charge transferred during the sucrose delivery and the quantal charge of mEPSCs recorded during the “baseline” period. *p 0.05. **p 0.01.
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glia is kept in a resting state by “off signals” released by active
neurons (Neumann, 2001; Pocock and Kettenmann, 2007) and
production of MVs is low (Verderio et al., 2012). It can be spec-
ulated that deficits in neurotransmission, by triggering microglia
activation andMV release,may enhance Sph and S1P production
to restore synaptic activity, a possibility that will be worth explor-
ing (Turola et al., 2012). However, during brain inflammation,
S1P synthesis in response to excessiveMVproduction fromover-
reactive microglia may trigger an excitatory-inhibitory unbal-
ance by selectively promoting transmitter release and resistance
to fatigue at excitatory synapses (Antonucci et al., 2012; Gabrielli
et al., 2015).
The impact of S1P production in response to microglia-
derived MVs may be even stronger at growth cones of immature
neurons, where ERK-mediated SynI dispersion has been shown
to enhance SV exocytosis (Schenk et al., 2005). S1P-induced
acceleration of glutamate release may influence motility of fil-
opodia and favor stabilization of nascent synapses through stim-
ulation of AMPA and kainate receptors (Verderio et al., 1994;
Chang andDeCamilli, 2001; Schenk et al., 2005;Gelsomino et al.,
2013). This effect adds to the complex action by which extracel-
lular S1P orchestrates neurite extension through other signaling
pathways, including Rac and Rho, which couple various S1P re-
ceptors to actin cytoskeleton (Toman et al., 2004; Milstien et al.,
2007). Relevant to this context, a clear role formicroglia in favor-
ing synaptogenesis has been recently established, in particular
during the early stages of brain development, when microglia
display functions, which are later on performed by astrocytes
(Schlegelmilch et al., 2011).Hence, the control of S1P production
by microglia-derived MVs at growth cones may provide a novel
mechanism for the dynamic regulation of neural circuits during
development.
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